Graves-Basedow disease is a cause of autoimmune hyperthyroidism characterized by the production of autoantibodies directed against the TSH receptor (TRAb), resulting in non-physiological stimulation of the thyroid gland and increased synthesis and secretion of T4 and T3. Its distinguishing feature is that the hormonal excess does not result from autonomous thyroid tissue activity, but from an immune signal that mimics the action of TSH and is often associated with a hypervascular diffuse goiter. In addition to thyroid involvement, the disease may present with extrathyroidal manifestations, the most typical of which is orbitopathy, also known as thyroid eye disease, resulting from immune mechanisms involving the retro-orbital tissues.
The clinical relevance of Graves-Basedow disease depends not only on the symptoms of thyrotoxicosis, but also on the risk of cardiovascular, skeletal, and metabolic complications and on the need for therapeutic management that balances efficacy, safety, and individual preferences among antithyroid medications, radioactive iodine, and surgery. ICD-10 code: E05.0.
Graves-Basedow disease is the most common form of hyperthyroidism in many clinical series and represents a paradigm of organ-specific autoimmune disease in which genetic, immunological, and environmental determinants interact over time. Its observed frequency varies according to diagnostic criteria, the availability of immunological testing for TRAb, and population characteristics, but the disease consistently shows a marked female predominance and a peak incidence in adulthood, although it may also occur in childhood or later in life. In clinical practice, its epidemiology is also influenced by the population’s iodine status, exposure to triggering factors, and the likelihood of recognizing oligosymptomatic or early forms.
The main risk factors include genetic predisposition and a family history of autoimmune thyroid disease, indicating that the risk is not specific to Graves disease alone, but reflects a broader vulnerability of the immune system to thyroid antigens. Among environmental factors, cigarette smoking is particularly important because consistent associations link it both to the development and to the severity of orbitopathy, making it a crucial modifiable determinant. Biological stressors, such as infections or major physiological changes, may also act as catalysts in predisposed individuals, not as sole causes but as facilitators of the breakdown of immunological tolerance.
Pregnancy and the postpartum period represent windows of particular immunological instability. Modulation of the immune response during pregnancy and the subsequent immune rebound after delivery may promote the onset or exacerbation of autoimmune thyroid disorders. This requires a high level of clinical suspicion in women presenting with compatible symptoms during the postpartum period and careful differentiation between Graves disease and thyrotoxicosis caused by thyroiditis. Age, the presence of other autoimmune diseases, exposure to excess iodine, and certain medications may influence the risk or clinical presentation, contributing to more complex clinical pictures and a more challenging differential diagnosis.
From a clinical perspective, it is important to consider that certain prognostic features and predictors of recurrence, such as elevated TRAb levels, increased thyroid volume, and smoking, overlap with epidemiological factors because they influence the probability of remission after medical therapy and therefore affect the observed distribution of therapeutic strategies within treated populations. In this sense, the real-world epidemiological profile of the disease is also shaped by therapeutic decisions, access to care, and the organizational models of treatment centers, in addition to the underlying biology of the condition.
Graves-Basedow disease results from a loss of immunological tolerance to thyroid antigens, with activation of helper T lymphocytes and B lymphocytes leading to the production of functionally active autoantibodies. The central pathophysiological element is represented by TRAb, autoantibodies directed against the TSH receptor, which in many forms act as thyroid-stimulating immunoglobulins (TSI). They induce receptor activation, increase intracellular cyclic adenosine monophosphate, and enhance all stages of follicular function, including iodide uptake through the sodium-iodide symporter, organification and iodination of thyroglobulin, coupling reactions, and thyroid hormone release. The result is sustained hyperthyroidism in which suppression of pituitary TSH does not deactivate the thyroid gland because stimulation is immunological and independent of central control.
From an etiological perspective, there is no single necessary and sufficient cause. The disease is an expression of multifactorial susceptibility. Genetic predisposition involves genes regulating antigen presentation, costimulation, and immune checkpoints, promoting a T-cell and B-cell response that is more likely to persist. Environmental factors such as smoking and certain iodine exposures may amplify inflammatory signals or alter antigenicity and the thyroid microenvironment, promoting clonal selection and affinity maturation of B lymphocytes directed against TSH receptor epitopes. The interaction between innate and adaptive immunity, with cytokine and chemokine production, supports chronic disease activity and the possibility of clinical fluctuations.
In Graves disease, the thyroid is not merely a stimulated organ, but an immunologically active tissue. Follicular cells may express adhesion molecules and proinflammatory signals that facilitate lymphocyte recruitment. Follicular hyperplasia and increased vascularization contribute to the diffuse goiter and to ultrasonographic evidence of increased blood flow, while greater secretory efficiency and peripheral conversion of T4 to T3 contribute to presentations dominated by T3 thyrotoxicosis during certain phases. Hormonal overproduction produces systemic effects, including increased energy turnover and thermogenesis, reduced peripheral vascular resistance with increased cardiac output, stimulation of gluconeogenesis and lipolysis, and increased bone turnover with predominant resorption and a tendency toward osteopenia and fractures if the condition persists.
Extrathyroidal manifestations, particularly orbitopathy, are explained by extension of the autoimmune response to tissues sharing related antigens or biological pathways. In orbital tissues, fibroblasts and stromal cells express receptors and molecules that may become targets of autoimmunity, resulting in inflammatory activation, glycosaminoglycan accumulation, edema, and remodeling of the extraocular muscles and adipose tissue. The clinical consequences include varying combinations of eyelid retraction, proptosis, diplopia, and, in severe forms, compressive optic neuropathy. Smoking amplifies these processes, making active disease more likely, increasing resistance to therapy, and influencing the orbital response after radioactive iodine treatment.
A final pathophysiological issue concerns the dynamics of autoantibodies. Their concentration and functional activity may vary over time, and the transition from an active to a quiescent phase does not always coincide with immediate normalization of TRAb levels. This variability underlies the fluctuating course of the disease, the possibility of remission after antithyroid therapy, and the risk of recurrence, and provides the rationale for using TRAb as useful biomarkers during follow-up and therapeutic risk stratification.
The clinical presentation of Graves-Basedow disease reflects the excessive effects of thyroid hormones on the heart, nervous system, skeletal muscle, and metabolism, with manifestations ranging from subtle symptoms to severe disease. During history taking, patients frequently report palpitations, heat intolerance, increased sweating, weight loss despite preserved or increased appetite, nervousness, insomnia, and reduced exercise tolerance. The main perceived disturbance is often a change in everyday performance, with irritability, emotional lability, and difficulty concentrating, particularly in demanding occupational settings. In some patients, especially older adults, symptoms may be less overt and dominated by cardiovascular manifestations such as atrial fibrillation or heart failure, making early recognition more difficult.
At the muscular level, proximal weakness may develop, with fatigability, cramps, and loss of muscle mass, while gastrointestinal manifestations include increased motility and frequent bowel movements. In women, menstrual irregularities and reduced functional fertility are common, whereas men may develop reduced libido and erectile dysfunction, which are often underestimated because they are attributed to other factors. The skin may appear warm and moist, and brittle hair or hair thinning may occur as a result of accelerated tissue turnover. Bone loss may remain clinically silent while progressing and is particularly relevant in patients with fracture risk factors.
On physical examination, the presence of a diffuse goiter, possibly accompanied by a thyroid bruit caused by hypervascularization, sinus tachycardia, and a fine tremor forms a suggestive combination of findings. Pulse pressure may be increased, with a relatively elevated systolic pressure and reduced diastolic pressure. Examination of the neck should assess thyroid size, consistency, and compressive signs, although compression is less typical in Graves disease than in large multinodular goiters. A distinguishing clinical feature is the presence of ocular manifestations, including foreign-body sensation, photophobia, tearing, eyelid retraction, periorbital edema, and proptosis. Diplopia, when present, suggests extraocular muscle involvement and requires a more structured assessment of disease severity and inflammatory activity.
Some extrathyroidal signs are less common but characteristic. Pretibial myxedema and acropachy are rare manifestations but are highly suggestive of Graves disease and are often associated with high TRAb titers and orbitopathy. The temporal sequence of symptoms must be considered carefully. In some patients, ocular signs may precede the full biochemical expression of hyperthyroidism or persist despite control of thyroid function, requiring parallel endocrinological and specialist ophthalmological management.
In the most severe presentations, hormonal excess may precipitate hemodynamic instability, arrhythmias, and rapid deterioration of the general condition, producing a spectrum that culminates in thyroid storm. This condition is defined not merely by markedly elevated thyroid hormone levels, but by a decompensated systemic response. Although rare, prevention depends on the timely recognition of uncontrolled thyrotoxicosis and identification of precipitating factors such as infections, trauma, or surgical procedures in patients who have not been adequately prepared.
Graves-Basedow disease should be suspected in the presence of a clinical picture compatible with hyperthyroidism, particularly when it is associated with signs suggesting thyroid autoimmunity and extrathyroidal manifestations. In practice, suspicion is high when symptoms such as palpitations, tremor, heat intolerance, and weight loss are accompanied by a diffuse goiter and is even stronger when typical ocular signs are present. The presence of orbitopathy, even when mild, strongly favors Graves disease over other causes of thyrotoxicosis because it represents a specific expression of the autoimmune process.
Suspicion should be particularly high in patients with new-onset atrial fibrillation, unexplained worsening of blood pressure control, or heart failure, because hyperthyroidism may be the underlying factor and Graves disease is a likely cause across many age groups. Apparently non-specific symptoms such as anxiety, insomnia, or reduced exercise tolerance also warrant thyroid assessment when accompanied by objective signs such as tachycardia or tremor. In women of reproductive age, menstrual irregularities associated with autonomic symptoms should prompt inclusion of thyroid evaluation in the initial assessment, particularly when there is a family history of thyroid disease or coexistence of other autoimmune disorders.
During pregnancy and the postpartum period, suspicion requires accurate differential diagnosis from thyroiditis. The presence of TRAb, a hypervascular diffuse goiter, and orbitopathy favors Graves disease, whereas thyroiditis often presents with different characteristics. Patients exposed to iodine or medications capable of altering thyroid function must also be considered, because these factors may modify the clinical presentation and make Graves disease biologically more unstable, with fluctuations requiring close monitoring.
Finally, Graves disease should be suspected when thyrotoxicosis is associated with a non-nodular thyroid gland and a typical biochemical pattern, but also when indirect signs are present, such as accelerated bone loss, muscular weakness, and worsening glycemic control. In these cases, timely assessment is not only diagnostic but preventive, because it reduces the risk of cardiovascular complications and progression of ocular manifestations, particularly in smokers.
The diagnosis of Graves-Basedow disease is based on a pathway integrating biochemical evidence of hyperthyroidism, immunological confirmation, and morphological and functional assessment of the thyroid gland. The first step is to demonstrate hyperthyroidism, with suppressed TSH and increased FT4 and/or FT3. During some phases, particularly early disease or specific variants, FT3 may be elevated while FT4 remains within the reference range, producing T3 thyrotoxicosis. This requires careful interpretation because the condition may be underdiagnosed when only FT4 is measured. Biochemical findings must always be interpreted in light of interfering medications, severe non-thyroidal illness, and conditions affecting binding proteins, because the objective is to distinguish true thyrotoxicosis from spurious laboratory abnormalities.
The key step in attributing hyperthyroidism to Graves disease is demonstrating autoimmunity directed against the TSH receptor. Measurement of TRAb is highly informative because it directly links the pathophysiological mechanism to the laboratory finding and, in many clinical settings, enables rapid diagnosis without the immediate need for additional functional investigations. TRAb also have prognostic value, because high and persistent titers are associated with a lower probability of remission after antithyroid therapy and a greater risk of extrathyroidal manifestations. In some patients, assessment of other thyroid autoantibodies may be useful, not to confirm Graves disease directly, but to characterize the overall autoimmune thyroid context.
Thyroid ultrasonography provides important additional information. Graves disease often presents with an enlarged thyroid gland, a relatively homogeneous echotexture, and markedly increased vascularity on color Doppler imaging, consistent with hyperactivity and hyperperfusion. Ultrasonography is also useful for identifying concomitant thyroid nodules, which may coexist and alter management because nodularity requires a dedicated assessment based on ultrasonographic criteria and, when indicated, cytological examination. When the diagnosis remains uncertain or differentiation from thyroiditis or nodular autonomy is required, thyroid scintigraphy with uptake measurement may provide decisive information. Graves disease typically shows diffusely increased uptake, whereas thyroiditis is characterized by reduced uptake because of follicular damage and release of preformed hormones.
Clinical and instrumental assessment should include evaluation of complications and target-organ involvement. An ECG is indicated in the presence of palpitations, tachycardia, or cardiovascular risk factors because arrhythmias and atrial fibrillation may be the first clinically relevant manifestation. When ocular symptoms are present, assessment should distinguish the activity and severity of orbitopathy. Moderate or severe cases may require specialist ophthalmological evaluation using standardized measurements and, when indicated, orbital imaging to assess the extraocular muscles and the risk of compression.
The differential diagnosis includes causes of thyrotoxicosis not resulting from increased hormone production, such as thyroiditis, exogenous thyroid hormone intake, and certain rare forms of hyperthyroidism. In specific settings such as pregnancy, the postpartum period, and treatment with interfering medications, diagnosis must balance immunological testing and functional assessment, with the ultimate objective not merely of identifying the cause, but of guiding a therapeutic strategy consistent with the patient’s risks and preferences.
Classification of Graves-Basedow disease is useful because it guides therapeutic choices and prognosis and helps integrate thyroid and extrathyroidal involvement. A first distinction concerns overt thyrotoxic disease with manifest hyperthyroidism versus milder or early forms in which hormonal excess is limited or only partially expressed. This grading is not purely laboratory based. It also depends on individual susceptibility to thyroid hormones and the degree of cardiovascular compensation, which explains why two patients with similar biochemical values may experience very different clinical effects.
A second classification dimension concerns the presence of extrathyroidal manifestations, particularly orbitopathy. Clinical management changes substantially when orbitopathy is active and moderate or severe because some thyroid-directed therapeutic choices may influence the course of ocular disease. Practical classification therefore distinguishes disease limited to the thyroid gland from systemic disease involving the orbit, skin, or, rarely, the osteoarticular system. Even in the absence of orbitopathy, future risk is not absent and depends on factors such as smoking, uncontrolled thyroid dysfunction, and antibody titers.
An additional criterion concerns the immunological profile and the probability of remission. High TRAb levels, a large goiter, and smoking are more frequently associated with recurrence after antithyroid medication withdrawal, whereas milder forms and declining antibody levels during therapy are associated with a greater probability of remission. This distinction is clinically relevant because it shifts the balance between attempting pharmacological remission and selecting definitive therapy. Special settings, including childhood, pregnancy, significant heart disease, and hepatic or hematological comorbidities, also represent specific management categories and require a functional classification based more on risk and tolerability than on biochemical findings alone.
Finally, severity includes the possibility of progression to an emergency such as thyroid storm. This event is not determined solely by thyroid hormone levels, but also by precipitating factors and the systemic response of the patient. Clinical classification must therefore identify patients at greatest risk of decompensation, including older adults with heart disease, patients with marked weight loss, and those with signs of heart failure, because they require a lower threshold for intervention and more intensive monitoring.
Treatment of Graves-Basedow disease aims to control symptoms rapidly, normalize thyroid hormone production, and reduce the risk of recurrence and complications through a choice between pharmacological and definitive strategies. The three therapeutic pillars are antithyroid medications, radioactive iodine, and thyroidectomy. The choice is individualized and depends on age, disease severity, goiter volume, comorbidities, reproductive plans, local availability, informed patient preferences, and the presence of orbitopathy. Symptomatic management with beta-blockers is often started promptly because it reduces palpitations, tremor, and adrenergic anxiety and stabilizes the patient while disease-specific therapy takes effect.
Antithyroid agents, with methimazole preferred in most settings, reduce hormone synthesis by inhibiting iodine organification and coupling reactions within thyroglobulin. They are commonly used as first-line therapy to restore euthyroidism and, in a proportion of patients, achieve remission after an appropriately long treatment course. The alternative agent, propylthiouracil, is reserved for selected situations, particularly for safety reasons during specific stages of pregnancy or when methimazole is not tolerated, with careful consideration of its risk profile. Antithyroid therapy requires clinical and biochemical monitoring and vigilance for adverse events because, although uncommon, some may be potentially severe, including agranulocytosis and hepatotoxicity. The choice between a titration strategy and combined regimens depends on the clinical setting and therapeutic objectives, while safety and stable euthyroidism remain the central criteria.
Radioactive iodine is a definitive therapy that reduces functioning thyroid tissue and commonly leads over time to hypothyroidism requiring replacement therapy, an expected and manageable outcome that must be monitored. The decision to use radioactive iodine must take into account the presence and risk of orbitopathy because, in some settings, it may be associated with worsening or new onset of ocular manifestations, particularly in smokers and in patients with active eye disease or high antibody titers. In such situations, glucocorticoid prophylaxis and a more cautious therapeutic choice become important components of the management plan. Total or near-total thyroidectomy is a definitive option particularly indicated in the presence of a large or compressive goiter, suspected malignancy, contraindications to radioactive iodine, or the need for rapid and stable control, including in some planned pregnancies or in patients with significant orbitopathy in whom rapid thyroid stabilization is essential.
Management of orbitopathy requires a parallel care pathway. Rapid restoration and maintenance of euthyroidism are shared objectives because both hyperthyroidism and hypothyroidism may worsen ocular disease. Smoking cessation is a central intervention. In active moderate or severe forms, immunomodulatory and anti-inflammatory treatments should be considered in experienced centers, and the strategy should be based on disease activity and severity, distinguishing inflammatory phases from fibrotic phases in which rehabilitative surgery becomes the predominant option.
In high-risk situations, including significant heart disease, advanced age, or severe hyperthyroidism, preventing decompensation and preparing patients adequately for definitive procedures are essential. The rationale is to reduce adrenergic burden and hemodynamic instability, ensure biochemical control, and establish a pathway that minimizes the risk of acute complications, including prevention of endocrine emergencies and careful management of infectious or surgical precipitating factors.
Follow-up in Graves-Basedow disease has several objectives: maintaining euthyroidism, monitoring therapeutic response and adverse events, preventing recurrence, and identifying cardiovascular, skeletal, and ocular complications at an early stage. During the initial phase, monitoring is more frequent because thyroid hormone levels may change rapidly after antithyroid therapy is started and because cardiovascular symptoms may require treatment adjustments. Biochemical monitoring is based on FT4 and FT3, whereas TSH may remain suppressed even after peripheral hormone levels have normalized and should not be used as the sole early indicator of response.
During antithyroid therapy, follow-up must assess not only normalization of biochemical parameters, but also tolerability and safety. Targeted clinical surveillance for symptoms suggesting significant adverse events is an integral part of management because timely recognition affects outcomes. Over time, the trend in TRAb levels may help estimate the probability of remission and guide decisions concerning treatment duration and withdrawal, although a comprehensive assessment must also include goiter size, smoking status, and the history of previous recurrences.
After radioactive iodine or surgery, follow-up focuses on the transition to hypothyroidism and on the correct initiation and titration of levothyroxine. Rapid achievement of a stable thyroid status reduces cardiovascular risks and also contributes to the control of orbitopathy. Clinical monitoring should include attention to changes in body weight, heart rate, blood pressure, and exercise tolerance because normalization of thyroid function does not always coincide with immediate recovery of physical performance, particularly when thyrotoxicosis has been prolonged.
Ocular surveillance is crucial. Even when hyperthyroidism is controlled, orbital disease may follow an independent course with phases of activity and stabilization. Ocular symptoms, diplopia, pain, photophobia, and signs of corneal exposure should be assessed periodically, with prompt specialist referral in the event of deterioration. Follow-up should reinforce preventive measures, particularly smoking cessation and maintenance of euthyroidism, and should coordinate endocrinological and ophthalmological care when extrathyroidal disease is present.
In patients at risk of osteometabolic complications, the duration and severity of thyrotoxicosis guide the need for assessment of bone mineral density and fracture risk. Similarly, in patients with atrial fibrillation or heart disease, cardiological follow-up and optimization of rhythm or rate control become part of integrated management because correction of thyroid dysfunction reduces the arrhythmic burden but does not automatically eliminate risk in every clinical profile.
The prognosis of Graves-Basedow disease is generally favorable when diagnosis is timely and treatment is appropriate, but it depends on initial severity, comorbidities, the presence of orbitopathy, and the risk of recurrence after medical therapy. A proportion of patients achieve remission after an adequate course of antithyroid treatment, whereas others experience recurrences that make definitive therapy more appropriate. The immunological profile, particularly persistent elevation of TRAb, and clinical factors such as a large goiter and smoking influence the probability of recurrence and therefore the long-term prognosis.
The main complications result from thyroid hormone excess and its effects on the cardiovascular system and skeleton. Cardiovascular complications include tachyarrhythmias and atrial fibrillation, which are clinically significant and may increase thromboembolic risk in predisposed patients and lead to heart failure in the presence of structural heart disease. Even in the absence of arrhythmias, thyrotoxicosis may reduce functional reserve and exercise tolerance, affecting quality of life and perioperative risk. Skeletal complications arise from increased bone turnover with predominant resorption, which may lead to osteopenia and fractures, particularly in patients with additional risk factors or prolonged uncontrolled thyrotoxicosis.
The most important extrathyroidal complication is orbitopathy because it may be disabling and, in severe forms, threaten vision through compressive optic neuropathy or exposure-related corneal damage. Both the risk and severity of orbitopathy are increased by smoking and persistent thyroid dysfunction. Timely, coordinated management reduces the probability of permanent damage, but ocular prognosis may remain partly independent of thyroid control alone and requires a dedicated approach based on activity and severity.
Therapy-related complications depend on the treatment selected. Antithyroid medications may cause adverse events requiring discontinuation or a change in strategy. Radioactive iodine and surgery frequently result in hypothyroidism requiring replacement therapy, a manageable condition that nevertheless requires continuous follow-up to prevent treatment-related hormonal imbalance. A central prognostic objective is the prevention of thyroid storm, a rare but potentially fatal event that occurs primarily when severe thyrotoxicosis is combined with a precipitating factor that exceeds the body’s compensatory capacity. Prevention depends on early diagnosis, adequate control before procedures, and aggressive management of infections or physical stressors in patients whose condition has not yet been stabilized.
Overall, Graves-Basedow disease can usually be effectively controlled with preservation of a satisfactory quality of life, provided that management is structured, individualized, and integrated, with attention to cardiovascular risks, bone health, and ocular involvement and with follow-up designed to anticipate recurrences and complications rather than respond to them after they occur.